Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

Phase 2positiveEloraTZPtirzepatidePositive

AI Analysis

Summary

Lilly's EloraTZP combination demonstrated superior efficacy versus tirzepatide 15 mg alone in a 48-week Phase 2b study, achieving greater weight loss (54.1 lbs vs 34.4 lbs) and A1C reduction (2.9% vs 2.4%) in adults with obesity and type 2 diabetes.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

EloraTZP demonstrated superior weight loss (54.1 lbs, 23.3% vs 34.4 lbs, 14.8%) and A1C reduction (2.9% vs 2.4%) compared to tirzepatide 15 mg

Importance:7/10

Sentiment:

0.85

obesitytype 2 diabetesweight lossglycemic controlphase 2b trialcombination therapy

Related Companies

$LLY

Read the original article

Published by PR Newswire Biotech on September 30, 2026 2:15 PM

Read Original